Cockayne syndrome: Clinical features, model systems and pathways

详细信息    查看全文

• 作者：Ajoy C. Karikkineth^a ; Morten Scheibye-Knudsen^b ; ^c ; Elayne Fivenson^b ; Deborah L. Croteau^b ; Vilhelm A. Bohr^b ; ^{vbohr@nih.gov}
• 关键词：Cockayne syndrome ; Progeria ; Neurodegeneration ; Mitochondria ; Transcription ; Parylation
• 刊名：Ageing Research Reviews
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：33
• 期：Complete
• 页码：3-17
• 全文大小：2538 K
• 卷排序：33

文摘

Cockayne syndrome (CS) is a disorder characterized by a variety of clinical features including cachectic dwarfism, severe neurological manifestations including microcephaly and cognitive deficits, pigmentary retinopathy, cataracts, sensorineural deafness, and ambulatory and feeding difficulties, leading to death by 12 years of age on average. It is an autosomal recessive disorder, with a prevalence of approximately 2.5 per million. There are several phenotypes (1–3) and two complementation groups (CSA and CSB), and CS overlaps with xeroderma pigmentosum (XP). It has been considered a progeria, and many of the clinical features resemble accelerated aging. As such, the study of CS affords an opportunity to better understand the underlying mechanisms of aging. The molecular basis of CS has traditionally been ascribed to defects in transcription and transcription-coupled nucleotide excision repair (TC-NER). However, recent work suggests that defects in base excision DNA repair and mitochondrial functions may also play key roles. This opens up the possibility for molecular interventions in CS, and by extrapolation, possibly in aging.